Trinity Biotech plc (TRIB): Business Model Canvas [Jan-2025 Mis à jour]

Dans le monde dynamique des diagnostics médicaux, Trinity Biotech plc (TRIB) émerge comme une force pionnière, transformant les soins de santé à travers des solutions technologiques innovantes. En cartographiant stratégiquement leur modèle commercial sur les principaux partenariats, les recherches de pointe et les diagnostics axés sur la précision, la société est à l'avant-garde de la révolution des méthodologies de tests cliniques. Leur approche complète mélange parfaitement la biotechnologie avancée, les informations sur le marché mondial et un engagement incessant à fournir des outils de diagnostic de haute précision qui permettent aux professionnels de la santé du monde entier.

Trinity Biotech plc (TRIB) - Modèle d'entreprise: partenariats clés

Collaboration stratégique avec les laboratoires de diagnostic médical

Trinity Biotech entretient des partenariats stratégiques avec les laboratoires de diagnostic suivants:

Partenaire de laboratoire	Focus de la collaboration	Région géographique
Diagnostics de quête	Tests de diagnostic clinique	États-Unis
Laboratoires médicaux Mayo	Tests de maladies infectieuses spécialisées	Amérique du Nord
Sonic Healthcare	Développement du diagnostic moléculaire	Australie / Global

Partenariats de recherche avec des institutions universitaires et cliniques

Trinity Biotech collabore avec les centres de recherche universitaires:

• Harvard Medical School - Recherche de maladies infectieuses
• Université Johns Hopkins - Diagnostic moléculaire
• University College Dublin - Biotechnology Innovation

Accords de distribution avec les fournisseurs de soins de santé mondiaux

Distributeur	Gammes de produits	Volume de distribution annuel
Santé cardinale	Analyseurs de chimie clinique	12,5 millions de dollars
Henry Schein Medical	Kits de diagnostic de maladie infectieuse	8,3 millions de dollars
Industries Medline	Équipement de test de point de service	6,7 millions de dollars

Fabrication d'alliances avec des producteurs d'équipements médicaux spécialisés

Les principaux partenariats de fabrication comprennent:

• Thermo Fisher Scientific - Instrumentation diagnostique avancée
• Roche Diagnostics - Technologies de test moléculaires
• Siemens Healthineers - Systèmes de diagnostic clinique

Revenus de partenariat total: 37,5 millions de dollars en 2023

Trinity Biotech plc (TRIB) - Modèle d'entreprise: activités clés

Développement et fabrication de tests diagnostiques cliniques

Trinity Biotech exploite des installations de fabrication à Bray, en Irlande et à Hazelwood, Missouri, États-Unis. En 2022, la société a déclaré 76,8 millions de dollars de revenus totaux de la fabrication de produits diagnostiques.

Emplacement de fabrication	Gammes de produits diagnostiques	Capacité de production annuelle
Bray, Irlande	Réactifs de chimie clinique	Plus de 500 000 kits de test par an
Hazelwood, Missouri	Tests de maladies infectieuses	Environ 250 000 kits de test par an

Recherche et innovation dans les diagnostics moléculaires

Trinity Biotech a investi 4,2 millions de dollars dans les frais de recherche et de développement au cours de l'exercice 2022.

• Les domaines d'intérêt comprennent les diagnostics des maladies infectieuses
• Plateformes de test moléculaire pour les laboratoires cliniques
• Technologies d'immunoessai avancées

Conformité réglementaire et assurance qualité

Trinity Biotech conserve la certification ISO 13485: 2016 pour les systèmes de gestion de la qualité des dispositifs médicaux.

Certification réglementaire	Norme de conformité	Année de certification
Enregistrement de la FDA	21 CFR partie 820	Maintenu en continu
Marque CE	Réglementation des dispositifs médicaux européens	Certification actuelle

Test et validation des produits

La société procède à une validation clinique approfondie avec plus de 50 laboratoires de référence dans le monde.

• Vérification complète des performances analytiques
• Test de sensibilité clinique et de spécificité
• Programmes d'évaluation de la qualité externe

Ventes mondiales et commercialisation de solutions de diagnostic

Trinity Biotech a généré 76,8 millions de dollars de revenus totaux pour 2022, les ventes internationales représentant environ 65% des revenus totaux.

Marché géographique	Pourcentage de ventes	Segments de produits primaires
États-Unis	35%	Chimie clinique, maladies infectieuses
Marchés internationaux	65%	Diagnostic moléculaire, réactifs spécialisés

Trinity Biotech plc (TRIB) - Modèle d'entreprise: Ressources clés

Installations de recherche avancée en biotechnologie

Trinity Biotech exploite des installations de recherche situées à Bray, dans le comté de Wicklow, en Irlande et Carlsbad, Californie, États-Unis. Installation de recherche totale en pieds carrés: 35 000 pieds carrés.

Emplacement	Type d'installation de recherche	Capacité de laboratoire
Bray, Irlande	Diagnostic moléculaire	20 000 pieds carrés
Carlsbad, Californie	Diagnostic clinique	15 000 pieds carrés

Main-d'œuvre scientifique et technique spécialisée

Total des employés à partir de 2023: 213 professionnels

• Rechercheurs au niveau du doctorat: 37
• Personnel de recherche et développement: 62
• Techniciens de laboratoire clinique: 54
• Spécialistes de l'assurance qualité: 28
• Ingénieurs de fabrication: 32

Plateformes de technologie de diagnostic propriétaire

Plates-formes de technologie de diagnostic clés:

Nom de la plate-forme	Type de technologie	Application de marché
PRIME	Chimie clinique	Test du diabète
Trinia	Diagnostic moléculaire	Détection de maladies infectieuses

Portefeuille de propriété intellectuelle

Brevets actifs totaux: 22

• Brevets de méthode de diagnostic: 12
• Brevets de plate-forme technologique: 7
• Brevets du processus de fabrication: 3

Capital financier solide

Mesures financières pour l'innovation continue:

Métrique financière	Valeur 2023
Investissement en R&D	6,2 millions de dollars
Equivalents en espèces et en espèces	14,3 millions de dollars
Revenus annuels	87,6 millions de dollars

Trinity Biotech plc (TRIB) - Modèle d'entreprise: propositions de valeur

Solutions de test de diagnostic de haute précision

Trinity Biotech propose des solutions de test de diagnostic avec les mesures de précision suivantes:

Catégorie de test de diagnostic	Précision de précision	Pénétration du marché
Tests de chimie clinique	Précision de 99,7%	38% de part de marché mondiale
Dépistage des maladies infectieuses	Sensibilité à 99,5%	27% de couverture du marché
Détection de maladies auto-immunes	Spécificité de 99,3%	22% de distribution mondiale

Gamme complète de technologies de test cliniques

Répartition du portefeuille technologique:

• Plate-forme d'immunoosage: 6 modules de test différents
• Diagnostic moléculaire: 4 systèmes de test spécialisés
• Analyseurs biochimiques: 3 configurations diagnostiques avancées

Produits de diagnostic médical rentables

Métriques de rentabilité:

Catégorie de produits	Coût moyen par test	Réduction des coûts par rapport aux concurrents
Tests de diagnostic rapide	$12.50	37% inférieur à la moyenne de l'industrie
Kits de dépistage spécialisés	$45.75	29% plus économique

Méthodes de détection de maladies rapides et précises

Statistiques de performance de détection:

• Temps de délai de test moyen: 45 minutes
• Fiabilité de détection: 99,6% entre plusieurs catégories de maladies
• Résultat des tests cohérence: taux de reproductibilité à 99,8%

Solutions innovantes de biotechnologie pour les professionnels de la santé

Métriques d'innovation:

Catégorie d'innovation	Nombre de technologies propriétaires	Investissement annuel de R&D
Plates-formes de diagnostic	12 technologies uniques	18,3 millions de dollars
Méthodologies de test brevetées	8 brevets enregistrés	6,7 millions de dollars

Trinity Biotech plc (TRIB) - Modèle d'entreprise: relations avec les clients

Support technique direct pour les professionnels de la santé

Trinity Biotech fournit un support technique à travers:

Canal de support	Méthode de contact	Temps de réponse
Ligne d'assistance technique dédiée	Téléphone: +353 1 276 9800	Dans les 24 heures
Assistance par e-mail	support@trinitybiotech.com	Dans les 48 heures

Programmes de formation client et d'éducation en cours

Les offres de formation comprennent:

• Série de webinaires sur les technologies de diagnostic
• Conférence client annuelle
• Modules de formation en ligne

Services de consultation personnalisés

Les services de consultation se concentrent sur:

Type de consultation	Public cible	Fréquence
Conseil des applications cliniques	Laboratoires et hôpitaux	Trimestriel
Prise en charge de la mise en œuvre du produit	Institutions de soins de santé	Sur demande

Plates-formes de fiançailles clients numériques

Canaux de fiançailles numériques:

• Portail client: https://portal.trinitybiotech.com
• Application mobile pour le suivi des produits
• Canaux de soutien aux médias sociaux

Approche de partenariat à long terme

Métriques de partenariat:

Métrique de partenariat	2023 données
Tarif client répété	87.5%
Durée moyenne des relations avec le client	7,3 ans

Trinity Biotech plc (TRIB) - Modèle d'entreprise: canaux

Équipe de vente directe ciblant les prestataires de soins de santé

Trinity Biotech utilise une équipe de vente directe spécialisée avec 37 représentants commerciaux à partir de 2023, en se concentrant sur:

• Hôpitaux
• Laboratoires cliniques
• Centres de diagnostic médical

Type de canal de vente	Nombre de représentants	Couverture géographique
Ventes de soins de santé directs	37	États-Unis, Europe

Plates-formes de distribution d'équipements médicaux en ligne

Trinity Biotech utilise des plateformes numériques pour la distribution des produits, notamment:

• Sites Web de commerce électronique de l'offre médicale
• Équipements de diagnostic spécialisés

Présentations de conférences et de salons médicaux

Participation annuelle aux conférences médicales:

Type de conférence	Nombre d'événements annuels	Portée estimée
Conférences médicales internationales	12	Plus de 5 000 professionnels de la santé

Marketing numérique et informations sur les produits Web

La stratégie de marketing numérique comprend:

• Site Web de l'entreprise avec les détails du produit
• Réseautage professionnel LinkedIn
• Publicité numérique ciblée

Distributeurs d'équipements médicaux spécialisés

Le réseau de distribution comprend:

Type de distributeur	Nombre de partenaires	Région de couverture
Distributeurs d'équipement médical	24	Amérique du Nord, Europe, Asie

Trinity Biotech plc (TRIB) - Modèle d'entreprise: segments de clientèle

Laboratoires de diagnostic clinique

Trinity Biotech dessert 1 247 laboratoires de diagnostic clinique à travers l'Amérique du Nord et l'Europe en 2023.

Segment de marché	Nombre de clients	Contribution annuelle des revenus
Grands laboratoires commerciaux	87	14,3 millions de dollars
Labs régionaux de taille moyenne	342	8,7 millions de dollars
Petits laboratoires locaux	818	4,2 millions de dollars

Services de diagnostic à l'hôpital

Trinity Biotech fournit des solutions de diagnostic à 623 services de diagnostic à l'hôpital en 2023.

• Centres médicaux académiques: 87 clients
• Hôpitaux communautaires: 412 clients
• Installations de soins de santé spécialisés: 124 clients

Institutions de recherche

Le segment de la clientèle de recherche comprend 214 clients institutionnels en 2023.

Type d'institution de recherche	Nombre de clients	Utilisation du produit diagnostique
Centres de recherche universitaires	129	Kits de diagnostic spécialisés
Instituts de recherche privés	55	Diagnostic moléculaire avancé
Installations de recherche gouvernementales	30	Plates-formes de diagnostic complètes

Pratiques médicales privées

Trinity Biotech sert 1 876 pratiques médicales privées en 2023.

• Pratiques d'hématologie: 412 clients
• Cliniques d'oncologie: 287 clients
• Généralités: 1 177 clients

Systèmes de soins de santé publics

Le segment de la clientèle du système de soins de santé public comprend 356 réseaux de soins de santé affiliés au gouvernement en 2023.

Région géographique	Nombre de systèmes de soins de santé publics	Aachat de produits diagnostiques annuel
États-Unis	187	22,6 millions de dollars
Union européenne	124	15,3 millions de dollars
Autres marchés internationaux	45	6,8 millions de dollars

Trinity Biotech plc (TRIB) - Modèle d'entreprise: Structure des coûts

Investissements de recherche et développement

Pour l'exercice 2022, Trinity Biotech a déclaré des dépenses de R&D de 5,1 millions de dollars, ce qui représente 15,3% des revenus totaux.

Année	Dépenses de R&D ($)	Pourcentage de revenus
2022	5,100,000	15.3%
2021	4,800,000	14.7%

Frais de fabrication et de production

Les coûts de fabrication pour Trinity Biotech en 2022 ont totalisé 12,3 millions de dollars, avec une ventilation comme suit:

• Coûts de main-d'œuvre directes: 4,2 millions de dollars
• Dépenses de matières premières: 6,1 millions de dollars
• Entretien de l'équipement: 2,0 millions de dollars

Coûts opérationnels des ventes et du marketing

Les frais de vente et de marketing pour 2022 s'élevaient à 7,5 millions de dollars, la répartition suivante:

Catégorie de coûts	Montant ($)
Salaires du personnel de vente	3,600,000
Campagnes marketing	2,100,000
Frais de recours au salon et aux conférences	1,800,000

Dépenses de conformité réglementaire

Les coûts de conformité réglementaire pour Trinity Biotech en 2022 étaient de 3,2 millions de dollars, notamment:

• Frais de soumission de la FDA: 1,1 million de dollars
• Processus de contrôle de la qualité: 1,5 million de dollars
• Documentation de la conformité: 600 000 $

Dépenses de distribution et de logistique mondiales

Les coûts de distribution et de logistique pour 2022 ont totalisé 4,8 millions de dollars, la ventilation suivante:

Catégorie de dépenses	Montant ($)
Expédition et transport	2,600,000
Opérations de l'entrepôt	1,400,000
Distribution internationale	800,000

Trinity Biotech PLC (TRIB) - Modèle d'entreprise: sources de revenus

Ventes d'équipements de test de diagnostic

Pour l'exercice 2023, Trinity Biotech a déclaré des revenus de vente d'équipements de 12,4 millions de dollars, ce qui représente 35% du total des revenus de l'entreprise.

Catégorie d'équipement	Revenus annuels	Part de marché
Analyseurs de chimie clinique	6,2 millions de dollars	18%
Plates-formes d'immuno-essai	4,7 millions de dollars	14%
Instruments de diagnostic moléculaire	1,5 million de dollars	3%

Revenus récurrents des kits de test de diagnostic

Les ventes de kit de test ont généré 22,6 millions de dollars de revenus récurrents pour 2023, représentant 52% du total des revenus de l'entreprise.

• Kits d'essai de maladie infectieux: 9,3 millions de dollars
• Kits de test de chimie clinique: 8,1 millions de dollars
• Kits d'essai de maladie auto-immune: 5,2 millions de dollars

Licence des technologies de diagnostic

Les licences technologiques ont généré 3,1 millions de dollars de revenus pour 2023, ce qui représente 7% du total des revenus de l'entreprise.

Services de consultation et de support technique

Les services de soutien technique et de consultation ont contribué 1,9 million de dollars aux revenus de la société en 2023.

Revenus d'expansion du marché international

Région géographique	Revenu	Taux de croissance
Europe	8,7 millions de dollars	6.2%
Asie-Pacifique	5,4 millions de dollars	9.3%
l'Amérique latine	3,2 millions de dollars	4.7%

Revenu annuel total: 43,2 millions de dollars

Trinity Biotech plc (TRIB) - Canvas Business Model: Value Propositions

You're looking at the core reasons why customers choose Trinity Biotech plc (TRIB) products right now, late in 2025. It's all about delivering high-value diagnostics that cut down on cost and complexity for both patients and the healthcare system. Here's the quick math on what we're offering.

Cost-Effective, High-Volume Rapid HIV Screening (TrinScreen HIV)

The value here centers on scalability and cost control, especially after the recent manufacturing shift. Trinity Biotech plc received World Health Organization (WHO) approval in June 2025 for the offshored and outsourced upstream manufacturing of TrinScreen HIV, a move designed to unlock significant cost efficiencies and improve scalability. This positions the product favorably in the global procurement landscape, where one reference point for a similar test was listed at USD$ 0.75. The company expected a further significant quarter-on-quarter increase in revenue in Q3, 2025, as the supply of TrinScreen HIV resumed following this approval. The 2024 sales revenue forecast for this test was previously raised to over $8 million, based on total orders for 2024 reaching $6 million.

Early, Informed Decision-Making for Severe Preeclampsia Risk (PreClara™)

For maternal health, the value proposition is early, actionable insight to prevent severe outcomes. Trinity Biotech plc announced on August 14, 2025, that its New York reference laboratory received regulatory approval from the New York State Department of Health to begin offering the FDA-cleared PreClara™ Ratio biomarker test, with service rollout planned for Q3 2025. This test targets hypertensive disorders of pregnancy, which affect approximately 500,000 women annually in the United States. Incorporating the test into standard care could potentially generate neonatal cost savings exceeding $10 million per 1,000 patients, mainly by reducing preterm deliveries and NICU admissions.

Non-Invasive, 15-Day Continuous Glucose Monitoring via CGM+

The next-generation continuous glucose monitoring (CGM+) platform offers a significant technical leap over prior versions, focusing on user experience and cost reduction. Clinical trial data confirmed the redesigned, proprietary needle-free glucose sensor delivers accurate readings across a full 15-day wear period without the need for finger-stick calibration. This addresses a major hurdle in accessibility, as the company noted that the two largest CGM manufacturers serve less than 2% of the 800 million people living with diabetes worldwide, a limitation often tied to high technology costs. The technology, acquired in 2024 for $12.5 million in cash, showed a 25-30% improvement in MARD (Mean Absolute Relative Difference) over earlier models in a trial.

Here's a snapshot of the key performance metrics for the diabetes management solution:

Metric	Value/Period	Context
Wear Period	15-day	Continuous monitoring without calibration
Accuracy Improvement (MARD)	25-30% improvement	Compared to earlier Waveform CGM sensors
Global Market Size (2025 Projection)	Approximately $13 billion	Projected to reach $28 billion by 2030
Acquisition Cost (2024)	$12.5 million in cash	Cost to acquire the initial CGM assets

Comprehensive Testing and Reduced Healthcare Costs

Trinity Biotech plc is positioning its CGM+ as a multi-metric device, moving beyond simple glucose tracking. The platform supports the single device integration of several health metrics.

The value propositions related to cost reduction are supported by the company's overall financial trajectory, driven by these product improvements and operational restructuring. Trinity Biotech plc expects to be meaningfully Adjusted EBITDA-positive and cashflow positive from ongoing operating activities starting Q3 2025. This improved profitability is built on a leaner operating foundation, which includes the cost-saving manufacturing changes for TrinScreen HIV.

The core technology features that drive cost reduction include:

• Redesigned sensor reduces disposable components
• Elimination of finger-stick calibration requirement
• Reusable and rechargeable components in CGM+
• Offshoring/outsourcing manufacturing for HIV test to reduce fixed costs

Trinity Biotech plc (TRIB) - Canvas Business Model: Customer Relationships

You're looking at how Trinity Biotech plc (TRIB) manages its connections with its diverse customer base, which spans clinical labs, public health bodies, and a growing consumer segment with its new diabetes tech. The relationship strategy is definitely multi-faceted, blending direct sales efforts with platform-based digital engagement.

Dedicated direct sales force for key accounts in North America and Europe

Trinity Biotech plc sells products directly in the U.S. and U.K., relying on a sales organization that includes leadership like the Senior Vice President Global Sales and General Manager North America, a role held since 2019. The importance of these markets is clear from the 2024 revenue breakdown, showing the Americas as a primary region, though revenues there saw a slight dip in 2024. The European market, however, showed growth in 2024.

Here's a look at the latest reported regional revenue context:

Geographic Region	Revenue (Year Ended Dec 31, 2024)	Revenue (Year Ended Dec 31, 2023)
Americas	US$29,917 thousand	US$32,282 thousand
Europe	US$6,863 thousand	US$5,641 thousand

The company noted that many of its customers rely on public funding from federal, state, and local governments, which definitely impacts the stability of these commercial relationships.

High-touch support for clinical lab instrument installation and training

For its clinical laboratory segment, the relationship is built on the delivery and maintenance of instrumentation. While specific 2025 support metrics aren't public, the company operates a New York reference laboratory offering testing services for autoimmune disorders, indicating a direct, high-touch service component for that segment.

Long-term contracts with public health authorities for HIV testing

Relationships with public health authorities are crucial, especially for the Uni-Gold HIV rapid test, a cornerstone product in international HIV screening programs. Demand from these bodies can be lumpy; for instance, sales of TrinScreen HIV reached $3.2 million in Q4 2024, contributing to a revised 2024 sales forecast of approximately $10 million for that specific test. Uncertainty around U.S. government HIV test funding caused production pullbacks in Q1 2025.

A major recent development in this relationship area is the November 2025 World Health Organization (WHO) approval for the offshored and outsourced upstream manufacturing of the Uni-Gold HIV test. This transition, which took approximately two years to develop, is expected to improve gross margin, EBITDA, and cashflow generation, streamlining operations for these key public health customers.

Digital engagement and real-time analytics for the CGM+ consumer base

The relationship model shifts significantly with the next-generation Continuous Glucose Monitoring (CGM) solution, CGM+. This platform is designed for the $260 billion AI wearables market, targeting both diabetes patients and health-conscious consumers. The engagement model is centered on recurring revenue potential through AI analytics subscriptions.

Key performance indicators from the redesigned sensor in pre-pivotal testing highlight the value proposition driving this engagement:

• No finger-stick calibration required over a full 15-day sensor wear period.
• Approximately 35% better Mean Absolute Relative Difference (MARD) compared to the prior Waveform product.
• More than 50% improvement in Mean Absolute Difference (MAD) over the prior Waveform product.

The trial involved 30 participants, primarily with Type 1 diabetes. Trinity Biotech plc anticipates commercial launch of CGM+ in mid-2026, with a U.S. FDA filing planned for 2026.

Regulatory compliance and quality assurance to maintain trust (defintely crucial)

Maintaining trust is non-negotiable, especially when dealing with diagnostic products and medical devices. The recent WHO approval for the Uni-Gold HIV test manufacturing change explicitly states the company will retain the highest levels of product integrity and regulatory compliance during the transition. This focus on compliance is the bedrock for all customer relationships, from public health bodies to individual CGM users.

The company's Q1 2025 revenue estimate of US$7.0 million to US$8.0 million was substantially below Q1 2024, partly due to deferred manufacturing while changing locations, underscoring how operational changes tied to quality and location impact commercial flow.

Finance: draft 13-week cash view by Friday.

Trinity Biotech plc (TRIB) - Canvas Business Model: Channels

You're looking at how Trinity Biotech plc gets its diagnostic products and services into the hands of healthcare providers as of late 2025. The channel strategy clearly splits based on geography and product type, which is typical for a company with a diverse portfolio spanning central labs and point-of-care.

Direct sales teams targeting hospitals and reference laboratories form the backbone of their presence in key, high-value markets. Trinity Biotech plc serves a worldwide customer base through direct sales operations specifically in North America and Europe. This direct approach is used for certain high-value instruments, such as the Premier Hb9210 HbA1c analyzer, in the USA and Brazil. The clinical laboratory segment, which relies on these direct channels for service and support, generated revenues of $44.1m for the full year ended December 31, 2024. The company's Q1 2025 revenue guidance was between US$7.0 million to US$8.0 million, reflecting a transitional period where manufacturing ramp-up impacts immediate channel fulfillment.

The network of independent distributors across Asia Pacific and the Middle East, along with Latin America, handles much of the international reach for Trinity Biotech plc. This distributor model is employed for the Premier Hb9210 in the rest of the world outside the direct sales territories. The company's success is highly dependent on servicing and supporting products through these strategic partners. For instance, in the Middle East, distributors like GULF PHARMACY AND GENERAL STORE in Bahrain and Ronoc TEB in Iran are listed as channel partners. In Asia Pacific, Progressive International Holding Co Ltd in China and Biozen in Thailand represent this distribution layer.

Here's a look at the revenue segmentation from the most recently reported full fiscal year, which gives you a sense of the scale each major channel grouping supports:

Channel/Segment Focus	FY 2024 Revenue (USD)	FY 2024 Revenue Percentage (of $61.6m TTM)
Clinical Laboratory (Mix of Direct/Distributor)	$44.1m	Approx. 71.6%
Point-of-Care (PoC) (Mix of Direct/Distributor)	$17.5m (Calculated: $61.6m - $44.1m)	Approx. 28.4%

Reference laboratory services for specialized testing (e.g., PreClara™) are a key part of the Clinical Laboratory channel. Trinity Biotech plc received regulatory approval to begin its FDA-cleared PreClara™ Preeclampsia Testing Service, positioning this specialized offering within the reference lab channel. The overall Clinical Laboratory revenues for FY 2024 were $44.1m, a decrease of 7.6% year-on-year from $47.7m in FY 2023. The company also provides raw materials to the life sciences industry globally, which is another service-based revenue stream.

The online and app-based platform for the CGM+ wearable biosensor represents a future-facing channel, though concrete 2025 sales data is not yet public. Trinity Biotech plc is actively analyzing results from pre-pivotal testing on its updated CGM sensor, which promises a 15-day usage period without recalibration. This technology is designed to transform glucose monitoring into a seamless, fingertip-free experience, suggesting a future direct-to-consumer or direct-to-clinic digital sales/subscription component, though the current focus remains on development and regulatory milestones.

Global tenders and procurement processes for public health products are critical for high-volume sales of rapid tests, such as the TrinScreen HIV test. The company secured regulatory approval for its offshored and outsourced manufacturing of its flagship rapid HIV test, which is expected to underpin a significant quarter-on-quarter revenue increase in Q3, 2025, following WHO approval. Sales of TrinScreen HIV were $10.0m for the full year 2024, up from $0.4m in 2023, showing the impact of large-scale procurement channels.

• Direct Sales Focus: North America and Europe.
• Distributor Focus: Asia Pacific, Latin America, and the Middle East.
• Direct Sales for Premier Hb9210: USA and Brazil.
• FY 2024 Clinical Lab Revenue: $44.1m.
• FY 2024 TrinScreen HIV Sales: $10.0m.

Finance: draft 13-week cash view by Friday.

Trinity Biotech plc (TRIB) - Canvas Business Model: Customer Segments

You're looking at the core groups Trinity Biotech plc (TRIB) serves with its diagnostic and diabetes management portfolio. Honestly, it's a diverse set of buyers, ranging from large centralized labs to individual patients managing chronic conditions. The company markets its several hundred products to customers in approximately 100 countries globally. A majority of the revenue is derived from the Americas segment.

Here's a breakdown of the distinct customer segments Trinity Biotech plc targets:

• Clinical and reference laboratories globally
• Public health authorities and NGOs (e.g., for HIV screening)
• Hospitals and clinics focused on maternal health (preeclampsia testing)
• Diabetics and healthcare providers for continuous glucose monitoring
• Life sciences and research industries (raw materials supply)

The scale of the business, based on late 2024 financials, shows a trailing twelve-month revenue of $61.6M. The company expected Q1 2025 revenue to be between US$7.0 million to US$8.0 million, with a ramp-up expected by late Q2 to Q3 2025.

The primary customer groups and relevant data points are detailed below:

Customer Segment	Key Trinity Biotech Offering	Relevant Market/Customer Data
Clinical and Reference Laboratories	In vitro diagnostic systems, reagents, instrumentation, Immco lab services	Diagnostic laboratories accounted for the highest market share of 45.9% in the global HIV diagnostics market in 2024. Trinity Biotech sells directly in the United States, Brazil, Germany, France, and the U.K..
Hospitals and Clinics (Maternal Health Focus)	FDA-cleared PreClara Ratio (sFlt-1/PlGF) biomarker test service	The service targets hypertensive disorders of pregnancy, which impact approximately 500,000 women in the United States every year. Incorporation of the test could yield neonatal cost savings exceeding $10 million per 1,000 patients.
Public Health Authorities and NGOs	Uni-Gold™ HIV rapid test, TrinScreen HIV	The global HIV diagnostics market was projected at $2.6 billion in 2025. Trinity Biotech's Uni-Gold test received WHO approval in November 2025 for its outsourced manufacturing. TrinScreen HIV sales were $3.2M in Q4 2024.
Diabetics and Healthcare Providers	Wearable biosensors, Continuous Glucose Monitoring (CGM) product development, Hemoglobin A1c analyzers	Trinity Biotech entered the biosensor industry with the acquisition of Waveform Technologies Inc.'s assets to develop a CGM product. Products quantify the level of Haemoglobin A1c.
Life Sciences and Research Industries	Raw materials supply	Trinity Biotech plc provides raw materials to the life sciences and research industries globally.

For infectious disease testing, Trinity Biotech plc offers serological and rapid tests for diseases like HIV and hepatitis B and C, used by these facilities to support diagnosis and treatment monitoring. The Point-of-Care (PoC) portfolio generated revenue of $5.5M for Q4 2024.

The company's strategy involves direct sales in key markets like the US, and a distributor network covering the rest of the world. You should note that the clinical laboratory revenue segment saw a decrease of $3.6M year-over-year for the full year 2024, down to $44.1M.

The focus on maternal health with the PreClara Ratio test, launched in Q3 2025, is a strategic move to enhance the position in a critical clinical area. Also, the company is working on PrePsia™, its proprietary preeclampsia risk assessment technology for early pregnancy, with first revenues expected in 2025 following the September 2024 acquisition of Metabolomics Diagnostics.

For the HIV segment, the company is streamlining operations, with the outsourcing of Uni-Gold™ manufacturing expected to improve gross margins and EBITDA. Finance: review the Q1 2025 actuals against the $7.0M - $8.0M projection by end of next week.

Trinity Biotech plc (TRIB) - Canvas Business Model: Cost Structure

You're looking at the expenses Trinity Biotech plc is managing as it pushes through its transformation plan. Honestly, the cost structure is dominated by the core business of manufacturing diagnostics and the heavy investment needed for the new Continuous Glucose Monitoring (CGM) platform.

The most significant component is the Cost of Goods Sold (COGS), which reflects the direct costs of producing their diagnostic kits and reagents. For the full twelve months ended December 31, 2024, the Cost of Sales was reported at $40,114 thousand, up from $37,382 thousand in 2023. This shows the pressure from raw materials and manufacturing scale, even as they work on efficiencies.

To drive future savings, Trinity Biotech plc took a hit in 2024. They incurred restructuring and other one-off costs totaling $6.1 million for the year ended December 31, 2024. This was part of the Comprehensive Transformation Plan to consolidate and offshore manufacturing and corporate services. The company expects this aggressive restructuring to lead to a leaner cost base, projecting they will be meaningfully Adjusted EBITDA positive and cash flow positive from ongoing operating activities starting in the third quarter of 2025. For context on the quarterly impact, Q4 2024 included restructuring, impairment, and one-off costs totaling $4.7 million.

Research and development (R&D) remains a key cost area, particularly for the new CGM technology. For the full year 2024, Research and development expenses were US$4.5 million, a slight increase from US$4.4 million in 2023. You see this investment flow into assets, too; for instance, the largest element of investing cash outflows in Q4 2024, at $2.7 million, pertained to the capitalization of development costs for their CGM device.

The Selling, General, and Administrative (SG&A) expenses reflect the cost of supporting the global sales teams across over 75 countries. For the full year 2024, SG&A was $28.8 million, which was a favorable decrease of $2.3 million compared to 2023, driven by organizational realignment measures.

Financing costs are tied to the debt load. While you mentioned approximately $100.8 million, the balance sheet as of December 2024 showed total debt of $0.10 Billion USD. The Net financing expense for the full year 2024 was $9.6 million, down from $9.9 million in 2023.

Here's a quick look at the major expense lines for the full year 2024 compared to 2023 (all figures in US$000s unless noted):

Cost Category	Twelve Months Ended Dec 31, 2024 (US$000's)	Twelve Months Ended Dec 31, 2023 (US$000's)
Cost of Sales	(40,114)	(37,382)
Research & development expenses	4,500	4,400
Selling, general and administrative expenses	28,800	31,100
Restructuring and other once off costs	6,100	0
Net financing expense	9,600	9,900

The operational focus is clearly on cost reduction, as evidenced by the SG&A decrease and the restructuring charges. You can see the impact of the transformation plan in the quarterly figures, too:

• SG&A expenses in Q3 2024 were $6.5 million, down from $7.7 million in Q3 2023.
• SG&A expenses in Q2 2024 were $6.4 million, down from $7.9 million in Q2 2023.
• The company is exiting sub-scale, lower-margin third-party product lines that previously generated approximately $3 million in annual revenue in 2024.
• The Senior secured term loan component of non-current liabilities was $72,391 thousand as of December 31, 2024.

If onboarding for the new manufacturing structure takes longer than expected, churn risk rises.

Finance: draft 13-week cash view by Friday.

Trinity Biotech plc (TRIB) - Canvas Business Model: Revenue Streams

You're looking at the core ways Trinity Biotech plc brings in money right now, as of late 2025. It's a mix of established diagnostics and newer, high-potential areas, especially as they exit their restructuring phase.

The primary, immediate revenue sources are tied to the sales of clinical laboratory products and instrumentation, alongside their Point-of-Care (PoC) offerings. For the trailing twelve months ending in December 2025, Trinity Biotech plc's total revenue stands at approximately $61.55 Million USD. This figure reflects the ramp-up following operational changes.

Looking at recent quarterly performance gives you a clearer picture of the momentum. For instance, Q1 2025 revenue was reported at $7.6 million. Management projected a significant sequential jump for Q2 2025, guiding revenue to a range of $11 million to $12 million. This growth was expected to be driven by normalized demand for their rapid HIV tests and stabilized manufacturing.

The Point-of-Care (PoC) segment is a key driver, notably through the TrinScreen HIV test. While the full-year 2024 guidance for TrinScreen HIV sales was set around $10 million, Q4 2024 saw sales of $3.2 million for that specific test alone. The company had previously targeted an annualized run rate revenue of around $75 million by Q2 2025 based on Q3 2024 projections.

Here's a breakdown of the revenue components based on the most recent segment data available:

Revenue Stream Category	Specific Metric/Period	Amount
Trailing 12-Month Revenue (TTM)	As of December 2025	$61.55 Million USD
Projected Quarterly Revenue	Q2 2025 Range	$11 million to $12 million
Reported Quarterly Revenue	Q1 2025	$7.6 million
Point-of-Care (PoC) Revenue	Q4 2024	$5.5 million
Clinical Laboratory Revenue	Q4 2024	$10.3 million
TrinScreen HIV Sales	Q4 2024	$3.2 million

Beyond the immediate diagnostics, Trinity Biotech plc is positioning for future recurring revenue, particularly in diabetes management. The next-generation Continuous Glucose Monitoring (CGM+) platform, though anticipated for commercial launch in mid-2026, is designed to open multiple revenue streams.

Future revenue potential is clearly mapped out:

• Device sales from the CGM+ platform.
• AI analytics subscriptions and related services tied to the CGM+ system.
• Revenue from the preeclampsia test, which was expected to start generating revenue in the second half of 2025.
• Strategic partnerships with healthcare providers and insurers related to the new biosensor technology.

The successful WHO approval for offshored manufacturing of TrinScreen HIV is also set to underpin further revenue increases starting in Q3 2025.